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Abstract
The frequency of stable DNA adducts in a target tissue can be used to assess biologically effective 
dose; however, the utility of the metric in a risk assessment context depends on the likelihood 
that the DNA damage will be manifested as mutation. Previously, we employed the Muta™Mouse 
system to examine the induction of lacZ mutants and DNA adducts following exposure to the well-
studied mutagenic carcinogen 3-nitrobenzanthrone (3-NBA). In this follow-up work, we examined 
the empirical relationships between total adduct frequency and mutant frequency (MF) in tissues 
and cultured cells following acute 3-NBA exposure. The results show a significant induction of DNA 
damage and lacZ mutants in liver, colon and bone marrow, as well as FE1 pulmonary epithelial 
cells. In contrast, lung and small intestine samples had low, but significantly elevated adduct levels, 
with no significant increases in lacZ MF. Additional analyses showed a significant relationship 
between the mutagenic efficiency of total adducts, measured as the slope of the relationships 
between MF and total adduct frequency, and tissue-specific mitotic index (MI). The lack of mutation 
response in lung, in contrast to the high in vitro MF in FE-1 lung cells, is likely related to the 100-fold 
difference in MI. The lack of small intestine mutagenic response may be related to limited metabolic 
capacity, differences in DNA repair, and /or chemically induced apoptosis that has been observed 
for other potent mutagens. The results indicate that interpretation of adduct frequency values in 
a risk assessment context can be improved by considering the MI of the target tissue; however, 
more generalised interpretation is hampered by tissue-specific variations in metabolic capacity and 
damage processing. The work provides a proof of principle regarding the use of the Muta™Mouse 
system to critically examine the health risks associated with tissue-specific adduct loads.
Introduction
Chemical modifications of nucleotides are a major cause of DNA 
damage and mutation; publications documenting the reaction of 
chemical mutagens with DNA date back to the late 1940s when 
Elmore et al. (1) showed that mustard gas, bis(2-chloroethyl)sulfide, 
reacts with DNA in vitro. Later work demonstrated that mustard gas 
induces N7-guanine alkylations in mouse DNA in vivo (2). In due 
course, analysis of covalently linked base modifications, commonly 
referred to as DNA adducts, became an essential tool for mechanistic 
investigations of chemical mutagens and environmental carcinogens.
In an in vivo context, the observed frequency of DNA adducts in 
a given tissue can be employed as a marker of internal dose and target 
tissue exposure (i.e., biologically effective dose). Adduct frequency at a 
given post-exposure time reflects the amount of a mutagen, or its reac-
tive metabolite, that is delivered to target tissues, reacts with DNA to 
form chemically stable products, and has not been removed by DNA 
repair. Thus, adduct frequency can be employed as a useful biomarker 
along the continuum from exposure to pathophysiologic outcome (3,4). 
Moreover, it has become increasingly clear that the frequency of stable, 
promutagenic DNA adducts in a target tissue may also have a role in 
facilitating risk assessment of mutagenic carcinogens in environmen-
tal and occupational settings and, as such, DNA adduct analysis has 
become an essential tool in molecular epidemiology (5,6). However, 
since regulatory decisions are based on mutagenic activity and induced 
mutation frequency (MF), rather than DNA damage and adduct fre-
quency, there is ongoing debate regarding the utility of adduct fre-
quency metrics in a health and disease risk context. More specifically, 
since there are several steps between adduct formation and mutation, it 
is generally acknowledged that adduct frequency can only be used as a 
dosimeter of internal dose, and hence, a biomarker of potential effect 
(7,8). The context for the use of DNA adducts in assessing disease risk 
has been addressed in several excellent reviews (7,9–16).
Preston and Williams (10) and Jarabek et  al. (9) describe key 
events in the DNA reactive mode-of-action (MOA) for suspected 
human carcinogens. The framework presented and discussed in 
these reviews recognises that the characteristics of a cancerous cell 
can be acquired via genetic mutation, and DNA damage can ini-
tiate the aforementioned multistep process resulting in mutation. 
Mutation fixation requires misreplication of the damaged template 
or misrepair of damaged DNA, and the multi-step cellular response 
to DNA damage, which involves complex dynamic interplay of dam-
age, repair and replication, determines the likelihood and nature of 
mutations (17). The process is eloquently discussed in the aforemen-
tioned works by Jarabek et al. (9) and Preston and Williams (10); in 
addition, Holmquist and Gao (18) provide a quantitative framework 
describing the ‘sequential steps of mutagenesis’, a concept initially 
presented by Thilly (19). Holmquist and Gao formulate the proba-
bility of a chemically induced mutation at a particular position along 
a gene sequence as the product of several key metrics, including the 
probability that the base will be chemically altered (damaged), the 
probability that the damage will not be repaired, and the probability 
that the damaged site will be misread by a polymerase.
The probability that a DNA adduct will elicit a mutation is some-
times referred to as ‘mutagenic or mutational efficiency’ (9,20,21). 
According to Jarabek et al. (9), the mutagenic efficiency associated 
with a specific type of chemically induced DNA damage (i.e., adduct) 
is determined by a variety of biochemical, physiological and genetic 
factors, including the type, chirality, local sequence context and sta-
bility of the adduct, the cell-, tissue- or organ-specific repair capacity, 
the frequency of cellular replication, the background level of dam-
age, and the likelihood of replicative by pass.
In contrast to DNA adducts, the health risks associated with the 
induction of mutations above background levels are well established, 
and mutagenesis has been empirically and mechanistically linked to 
cancer and heritable genetic diseases (22–24). Consequently, induc-
tion of mutation and/or chromosomal damage is routinely used as 
an endpoint for the regulatory evaluation of industrial chemicals, 
food additives and therapeutic products (25–27). However, the 
most common regulatory in vivo assays employed to assess muta-
genic activity are restricted to haematopoietic cells (e.g., bone mar-
row, reticulocytes, mature red blood cells), and indicators of DNA 
damage (e.g., adducts, unscheduled DNA synthesis, etc.) are used to 
assess exposure of target and non-target tissues, and/or to provide 
information on the mode of action for suspected carcinogens. More 
recently, transgenic rodent assays (e.g., Muta™Mouse, Big Blue® 
Mouse and Rat, lacZ Plasmid Mouse, gpt delta mouse and rat) have 
afforded the ability to assess mutation induction in virtually any tis-
sue; and moreover, investigate empirical relationships between DNA 
damage frequency and induced MF in the same animals and tissues 
(28,29). This type of analysis can permit an evaluation regarding 
the utility of DNA adduct frequency; more specifically, it’s potential 
to predict the likelihood of mutations in various tissues following 
exposure to environmental mutagens and/or mutagenic carcinogens.
3-Nitrobenzanthrone (3-NBA) is a carcinogenic product of die-
sel combustion (30) that is highly mutagenic in vitro and in vivo. It 
induces squamous cell carcinomas in the lungs of F344 rats follow-
ing intratracheal instillation (31), but did not initiate tumour for-
mation in NMRI mouse skin (32). Mechanistic investigations have 
shown that the nitro group is reduced by cytosolic nitroreductases 
such as NAD(P)H:quinone oxidoreductase (33–35). The reduced 
metabolite, 3-aminobenzanthrone (3-ABA), is predominantly acti-
vated by cytochrome P450 (CYP) isozymes 1A1 and 1A2, and both 
3-NBA and 3-ABA can yield an unstable hydroxylarylamine inter-
mediate (i.e., N-hydroxy-3-aminobenzanthrone or N-OH-3-ABA) 
(36). N-acetyltransferases (NATs) and sulfotransferases (SULTs) 
can further metabolise the unstable intermediate to ultimately yield 
highly reactive cations (e.g., nitrenium or carbenium) (33,35). The 
reactive metabolites of 3-NBA and 3-ABA have been shown to form 
several stable DNA adducts (37–39). The average human intake of 
3-NBA by inhalation is ~90 pg/day; however, intake by populations 
in areas of high air pollution can be considerably greater (33).
Three of the five spots detected in the autoradiographic profiles 
of 32P-postlabelled 3-NBA-induced DNA adducts have been identi-
fied as dA-N6-3-ABA (Spot 1), dG-N2-3-ABA (Spot 3)  and dG-C8-
N-3-ABA (Spots 4/5) (37,38), and Arlt et  al. (36–38,40,41) have 
shown that 3-NBA-DNA adduct profiles are the same for a variety 
of murine tissues. Bieler et al. (42) and Kawanishi et al. (43) inves-
tigated the formation and persistence of 3-NBA adducts, and noted 
that dG-N2-3-ABA adducts are the most persistent. Results showed 
that 85% of dG-N2-3-ABA adducts remain after 24 hrs, and they 
are still detectable 20 weeks after treatment (Supplementary Table 1, 
available at Mutagenesis Online). This suggests that they are less likely 
to be repaired (43), perhaps by avoidance of global genomic nucleo-
tide excision repair (44), and consequently more likely to contribute 
to induction of mutations. Arlt et  al. (37) note that the persistence 
and relative prevalence of this adduct, as well as dG-C8-N-3-ABA, 
is consistent with the earlier observation (45) of the induction of GC 
to TA transversions in the cII gene of Muta™Mouse liver following 
i.p. exposure. This is consistent with the works of Kawanishi et al. 
(43,46) and Pande et al. (17) that employed site specific mutagenicity 
assays to show that the dG-N2-3-ABA (Spot 3) and dG-C8-N-3-ABA 
(Spots 4/5) adducts are promutagenic, inducing GC to TA transver-
sions in both bacterial and human cells. Previously, we documented 
the formation of stable DNA adducts and lacZ transgene mutations in 
Muta™Mouse in vivo and Muta™Mouse cells in vitro following dif-
ferent exposures to 3-NBA (37). In this communication we examine 
the empirical relationships between total adduct frequency and total 
MF in Muta™Mouse tissues (i.e., liver, lung, colon, small intestine and 
bone marrow) and cultured Muta™Mouse cells exposed to 3-NBA.
Materials and methods
Test compound
3-Nitro-7H-benz[de]anthracen-7-one (3-nitrobenzanthrone or 
3-NBA) (CAS No. 17117-34-9; purity 99%) was obtained from the 
Sigma Library of Rare Chemicals (Sigma-Aldrich, Oakville, Ontario, 
Canada).
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Animal treatment and tissue collection
Transgenic animals (strain 40.6; BALB/c × DBA/2) were obtained 
from a breeding colony maintained at the Health Canada Animal 
Care Facility. Animals were maintained and treated under conditions 
approved by the Health Canada Animal Care Committee. Male mice 
(16–20 weeks) were maintained on a 12-h light–dark cycle and pro-
vided with fresh water and Rodent Chow (Ralston Purina, Hazleton, 
PA, USA) ad libitum. Each experiment involved up to five animals per 
dose group, and the data presented were compiled from two separate 
rounds of exposure. The maximum number of replicate animals per 
dose group was 8, the minimum was 5. A single dose of 25, 50 or 
75 mg/kg body weight 3-NBA in olive oil was administered by oral 
gavage. Following the single treatment, tissues were collected at 18 h 
for analysis of DNA adducts in all tissues and lacZ transgene muta-
tions in bone marrow and intestinal epithelium, at 3 days for analysis 
of lacZ mutations in bone marrow, intestinal and colonic epithelium 
and liver, and at 28 days for analysis of lacZ mutations in liver, intesti-
nal and colonic epithelium, and lung. Mice were killed by cervical dis-
location and liver, lung, colon, small intestine and bone marrow were 
removed, frozen in liquid nitrogen and stored at ‒80°C until DNA 
isolation. The caecum was routinely used to locate the end of the intes-
tine and the start of the colon. To obtain bone marrow, femurs were 
flushed with cold phosphate-buffered saline (PBS), the solution cen-
trifuged at 10 000g for 1 min and the pellet stored at ‒80°C. Colonic 
and intestinal epithelium were rinsed with cold PBS to remove luminal 
contents, and the epithelial layer stripped from supporting tissue by 
inverting the tissue in 0.075 M KCl with 20 mM EDTA and repeatedly 
forcing it in and out of a needleless 5-ml syringe (47). This processing 
permitted liberation of the epithelial layers, and significantly reduced 
the likelihood of microbial contamination of murine DNA prepara-
tions. Minced or homogenised tissues were digested overnight in lysis 
buffer, and the DNA extracted and handled as previously described 
(48,49). Table 1 provides a summary of the tissue analyses conducted.
FE1 cell culture and treatment
FE1 is a stable epithelial cell line derived from Muta™Mouse lung 
(49). Cells were cultured in a 1:1 mixture of Dulbecco’s modified 
Eagle’s medium and F12 nutrient mixture supplemented with 2% 
(v/v) foetal bovine serum, 100 U/ml penicillin G, 100 mg/ml strepto-
mycin sulphate and 1 ng/ml murine epidermal growth factor (EGF) 
(GIBCO–Invitrogen, Burlington, Ontario, Canada).
2–3  ×  105 cells were seeded on 100-mm culture dishes and 
incubated overnight to ~20% confluence. The following morning 
cells were exposed for 6 h to a series of 3-NBA concentrations in 
serum-free medium, or a solvent control in serum-free medium. 
Cells were then washed twice with PBS and incubated for 72 h (i.e., 
72 h sampling time). Genomic DNA was isolated as described previ-
ously (50,51). Briefly, cells were incubated overnight at 37°C in lysis 
buffer containing 1% sodium dodecyl sulphate and 1 mg/ml fresh 
proteinase K (GIBCO–Invitrogen). Lysates were extracted with phe-
nol–chloroform (1:1) followed by chloroform, and sodium chloride 
added to a final concentration of 0.2 M. The DNA was precipitated 
in two volumes of ethanol, spooled onto a sealed Pasteur pipette, 
washed in 70% ethanol and dissolved in 15–100 µl of TE buffer 
(10 mM Tris and 0.1 mM EDTA, pH 7.6).
LacZ mutation analysis
Total transgene mutant frequency (MF) was determined using the 
P-gal-positive selection assay described elsewhere (28,51). Briefly, 
λgt10lacZ copies were rescued from genomic Muta™Mouse DNA 
using the Transpack™ system (Agilent Technologies, Mississauga, 
Ontario, Canada). Packaged phage preparations were mixed with 
host bacteria (50) and allowed to adsorb for 25 min at room temper-
ature. An aliquot of the phage-bacteria mix was diluted and plated 
on non-selective minimal agar to determine total titre (i.e., plaque 
forming units or pfu). The remaining phage-bacteria mixture was 
plated on minimal agar with the selective agent, 0.3% w/v phenyl-
ß-D-galacto-pyranoside (P-gal; Sigma-Aldrich). Both were incubated 
overnight at 37°C. Total MF was expressed as the ratio of mutant 
plaques to total pfu. Mutant plaques were not collected for lacZ 
sequencing; hence, MF values are not clonally corrected.
DNA adduct analysis using 32P-postlabelling
DNA adducts were measured using the butanol enrichment ver-
sion of the 32P-post-labelling method as described previously (52,53), 
with minor modifications. DNA samples from the mutation analy-
ses (4 µg) were digested with micrococcal nuclease (120 mU, Sigma-
Aldrich, Gillingham, UK) and calf spleen phosphodiesterase (40 mU, 
Calbiochem, Nottingham, UK), extracted with butanol and labelled 
as reported. Chromatographic conditions for thin-layer chromatogra-
phy (TLC) on polyethyleneimine-cellulose (Macherey-Nagel, Düren, 
Germany) were D1, 1.0 M sodium phosphate, pH 6.0; D2, 4 M lithium 
formate and 7 M urea, pH 3.5 and D3, 0.8 M lithium chloride, 0.5 M 
Tris and 8.5 M urea, pH 8.0. DNA adduct levels (relative adduct label-
ling or RAL) were calculated from the adduct counts per minute (cpm), 
the specific activity of [γ-32P]ATP and the amount of DNA used. Results 
were expressed as DNA adducts per 108 nucleotides (nt). In all cases, 
RAL values represent the sum of a cluster of 5 adduct spots detected 
via TLC 32P-postlabelling (see (37,38,40)). In some cases limitations in 
the amount of DNA obtained from certain tissues (e.g., bone marrow), 
and the low levels of 3-NBA-induced adducts, restricted the ability to 
detect adducts in all replicates. Consequently, although most dose-tissue 
combinations yielded 5 replicate measurements, some bone marrow 
samples (e.g., 25 mg/kg) yielded only 2 replicate measurements.
Data analysis
All raw data are available from the corresponding author on request.
Not all endpoints were assesses for all samples (see Table 1). For 
most dose-tissue combinations 5–8 biological replicates were ana-
lysed for lacZ MF, and five replicates analysed for RAL. In some 
cases, DNA adduct levels were near the detection limit and fewer 
than five replicates yielded reliable values (e.g., bone marrow). In 
vitro lacZ MF results are based on 2 (0.1 µg/ml only) to 8 replicates; 
only two replicates per dose were analysed for DNA adduct levels.
Table  1. Summary of Muta™Mouse tissue analyses following a 
single gavage administration of 3-NBA
Tissue Post-exposure sampling time
18 h 3 days 28 days
Bone marrow Adducts, lacZ  
mutations
lacZ  
mutations
Intestinal epithelium Adducts, lacZ  
mutations
lacZ  
mutations
lacZ  
mutations
Colonic epithelium Adducts lacZ  
mutations
lacZ  
mutations
Liver Adducts lacZ  
mutations
lacZ  
mutations
Lung Adducts lacZ  
mutations
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MF and RAL data were analysed via Poisson regression using SAS 
version 9.1 (SAS Institute, Cary, NC, USA). For MF analyses the natu-
ral log of total plaque count was used as an ‘offset’ (i.e., regression 
variable with a constant coefficient of 1.0 for each observation). Log-
linear relationships between mutant count or RAL and concentration 
or dose were specified by a natural log link function. Type 1, or sequen-
tial analysis, was employed to examine the statistical significance of the 
chemical treatment, and post hoc custom contrasts statements were 
employed to evaluate the statistical significance of responses at selected 
doses or concentrations. Ordinary least-squares linear regression anal-
ysis was employed to investigate empirical relationships between MF 
for a selected tissue and sampling time and total RAL in the same tis-
sue at 18 h sampling time. Since the numbers of observations for each 
endpoint in a given tissue (i.e., total RAL and MF) were not identical 
and varied between 2 and 8, unbiased analyses of the dose-matched 
empirical relationships between total RAL and MF required repeated 
random subsampling by dose, and subsequent iterative regression 
analysis (i.e., bootstrapping or Monte Carlo analysis). One thousand 
sampling iterations, with subsequent regressions, provided unbiased 
statistical metrics, including the bootstrapped slope of the relation-
ship between MF and total RAL (i.e., the mutagenic efficiency of total 
adducts) as well the bootstrapped r2, F ratio and ANOVA P value. 
Subsequent analysis of variance was employed to compare mean slopes 
across tissues, and ordinary least-squares linear regression analysis was 
employed to investigate the empirical relationship between the muta-
genic efficiency of total adducts and mitotic index (i.e., the ratio of 
the number of cells in mitosis to the total number of cells in a popu-
lation). Since the Muta™Mouse MF analysis did not investigate the 
mutagenicity of individual adducts, it was not possible to investigate 
adduct-specific mutagenic efficiency (9,20,21). Since tissue-specific MI 
(mitotic index) values are not available for the Muta™Mouse, adult 
rodent values were collected from the scientific literature. Mean val-
ues used for the presented analyses are based on data collected from a 
minimum of four separate studies per tissue (54–67). Since the number 
of MI values varied from a low of 4 (lung) to a high of 15 (liver), it 
was necessary to employ the aforementioned Monte Carlo approach 
to obtain an unbiased assessment of the relationship between the 
mutagenic efficiency of total adducts and MI. Regression diagnostics 
(e.g., Studenised residuals, leverage values) were employed to examine 
the influence of individual observations on the outcome of the analy-
ses (68). Individual predictions of mutagenic efficiency for a given MI 
employed the method described by Gujarati (69).
Results
Previous work demonstrated a disconnect between the levels of total 
3-NBA-induced DNA adducts and the levels of induced transgene 
mutations in several tissues, for a variety of short- and longer-term 
exposure regimens. The present study investigated the empirical rela-
tionship between total DNA adduct levels in selected tissues observed 
18 h following a single oral administration of 25, 50 or 75 mg/kg 
3-NBA, and total MF in the same tissues 18 h (bone marrow, small 
intestine), 3 days (bone marrow, liver, small intestine, colon) or 28 days 
(bone marrow, liver, small intestine, colon, lung) after treatment. The 
in vivo RAL results observed at 18 h after a single acute dose are new 
data, while the MF data include new data, as well as those previously 
published (37,48). In addition, investigation of the MF-RAL relation-
ship in the present study incorporates published data on RAL and MF 
in FE1 cells following in vitro exposure to 0.1, 1, 3 and 10 µg/ml (37).
The in vivo lacZ transgene mutagenicity results (Figure 1) show 
statistically significant induction of mutations in bone marrow (18-h 
and 3-day sampling), liver (28-day sampling), and colonic epithe-
lium (3- and 28-day sampling). The most marked increases were 
observed in colon, followed by bone marrow and liver. No signifi-
cant increases in MF were observed in colonic epithelium (18-h 
sampling), liver (3-day sampling), lung (28-day sampling) and intes-
tinal epithelium (18-h, 3- and 28-day sampling). With respect to in 
vitro lacZ transgene mutagenicity, the results presented in Arlt et al. 
(37) showed a significant increase in MF at 1, 3, and 10 µg/ml. The 
0.1 µg/ml concentration did not elicit a significant increase in MF.
The in vivo RAL results show a statistically significant increase in 
adduct frequency 18 h after a single oral dose for bone marrow, liver, 
Figure 1. Mean lacZ mutant frequency (MF) in selected Muta™Mouse tissues following a single oral 3-NBA administration of 25, 50 and 75 mg/kg. Sampling 
times ranged from 18 h (bone marrow) to 28 days (liver and colon). For all results shown Poisson regression revealed a significant treatment effect with P < 0.001 
(Type 1 chi-square). Asterisks show the results of custom contrasts between individual doses and the concurrent control (based on the asymptotic chi-square 
distribution of the likelihood ratio). *P < 0.05, **P < 0.01, ***P < 0.001. Error bars show one standard error of the mean. Values on each bar show the number 
of biological replicates (animals). No significant increase in MF observed for the following, which are not shown: colonic epithelium (18 h), liver (3 days), lung 
(28 days) and intestinal epithelium (18 h, 3 and 28 days).
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intestinal and colonic epithelium and lung (Figure 2). The greatest 
increases in total RAL were seen in liver and colon, with an appar-
ent plateau at 50–75  mg/kg. Autoradiographic profiles showed a 
pattern of five adduct spots that has been reported previously (37). 
No adducts were detected in control tissues (see Figure 3). Earlier 
studies characterised the structure of these adducts, which have been 
identified by HPLC analyses of individual spots and mass spectrome-
try using authentic standards (38,39). Arlt et al. (38), which employed 
the same 32P-postlabeling methodology as that employed herein, 
prepared 3-NBA-derived DNA adducts and used them as authentic 
standards to determine the identity of adducts formed in vivo. More 
specifically, three of the spots were identified as 2-(2′-deoxyadenosin-
N6-yl)-3-aminobenzanthrone (dA-N6-3-ABA, spot 1), 2-(2′-deoxy-
guanosin-N2-yl)-3-aminobenzanthrone (dG-N2-3-ABA, spot 3), 
and N-(2′-deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-C8-N-
3-ABA, spots 4/5) (38). The adduct profiles indicate that the dG-
N2-3-ABA adduct (spot 3) is always the most common, accounting 
for between 37% (bone marrow, 25 mg/kg) and 46% (lung, 75 mg/
kg) of the total RAL. Spot 2, an as-yet-unidentified dA adduct, and 
dG-C8-N-3-ABA (spots 4/5) are the next most common adducts, 
accounting for approximately 15% (colon, 25 and 50  mg/kg) to 
38% (lung, 25 and 50 mg/kg), and 8% (lung, 25 and 50 mg/kg) to 
Figure 2. Mean total RAL (relative adduct labelling) in selected Muta™Mouse tissues following a single oral 3-NBA administration of 25, 50 and 75 mg/kg. All 
observations were made 18 h after dosing. Adducts were not detected in any of the control animals. For all results Poisson regression showed a significant 
treatment effect with P < 0.001 (Type 1 chi-square). Asterisks show the results of custom contrasts between individual doses and the concurrent control (based on 
the asymptotic chi-square distribution of the likelihood ratio). **P < 0.001, ***P < 0.0001. Error bars show one standard error of the mean. All means are based 
on five biological replicates, except bone marrow 25 mg/kg for which n = 2.
Figure  3. The relative abundance of each 3-NBA DNA adduct in the autoradiographic profile (i.e., spots 1–5). Adduct profiles for indicated in vivo tissues 
represent the single oral dose of 50 mg/kg 3-NBA. The adduct profile for FE1 cells represents the 3 µg/ml 3-NBA treatment. RAL, relative adduct labelling. For 
in vivo tissues, N = 5. For in vitro FE1 cells, N = 2. Error bars show one standard error of the mean. The inset shows typical autoradiograms illustrating the 
positions of spots 1 through 5 (i.e., 50 mg/kg 3-NBA in vivo and 3 µg/ml 3-NBA in vitro). The identities of the individual adducts are described in the text. Detailed 
summaries of adduct proportions for all samples across all doses are provided in Supplementary Figure 1, available at Mutagenesis Online.
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23% (colon, 25 and 50 mg/kg, liver, 50 mg/kg), respectively. A typi-
cal distribution of adduct proportions in each tissue, as observed at 
50 mg/kg, is shown in Figure 3. A detailed overview of adduct pro-
portions for all tissues and all doses is presented in Supplementary 
Figure 1, available at Mutagenesis Online.
With respect to the previously published in vitro RAL results 
(37), a significant increase in RAL was observed at 0.1, 1, 3, and 
10  µg/ml (i.e., averages of 5.3, 10.2, 128.6, 173.1 total RAL per 
108 nucleotides, respectively). No adducts were detected in the unex-
posed cells, and the adduct profile is similar to that observed in vivo 
(Figure 3a and b in [37]). Interestingly, the maximum adduct lev-
els observed in FE1 cells are greater than those observed in some 
Muta™Mouse tissues (e.g., lung, intestine, bone marrow). More 
specifically, the maximum adduct levels observed in intestine, bone 
marrow and lung (i.e., 7.5, 3.1 and 6.4, respectively) are in the same 
range as that observed for in vitro exposures to less 1 µg/ml. In con-
trast, the maximum adduct levels observed in liver and colon (i.e., 
88.0 and 72.2, respectively) are comparable to levels observed for in 
vitro exposures of 3 µg/ml. Figure 3 also illustrates the typical dis-
tribution of adduct proportions in vitro observed at 3 µg/ml. Similar 
to the in vivo results, the results show that the dG-N2-3-ABA adduct 
(spot 3)  is predominant, followed by spots 4/5 and 2, decreasing 
in that order. Interestingly, the in vitro FE1 frequencies of spot 1 
(i.e., lower) and 4 (i.e., greater) differ from what was observed in 
vivo. A detailed overview of adduct proportions for FE1 cells at all 
concentrations is provided in Supplementary Figure 1, available at 
Mutagenesis Online.
In summary, Figure 3 shows the predominance of the dG-N2-3-
ABA adduct (spot 3) in all tissues as well as FE1 cells; spots 2 and 
then 4/5 (dG-C8-N-3-ABA) are generally the next most prevalent, 
respectively. Exceptions to this overall pattern are spot 1 in FE1 cells 
(low), and spot 4 in FE1 cells (high) and lung (low). The frequency 
of spot 2 is quite variable ranging from a low of 12.8 and 14.6% for 
FE1 cells and colon, respectively, to a high of 38% in lung.
Interestingly, the dose-related increases in total MF and total 
adducts (Figures 1 and 2) indicate that some of the dose–response 
relationships are distinctly non-linear, reaching zero order kinetics 
at elevated 3-NBA doses (e.g., bone marrow MF, liver RAL, etc.). 
Detailed investigations regarding the nature of 3-NBA dose–response 
relationships are outside the scope of this work, which addresses 
the relationships between total MF and total RAL across a series 
of matched doses. Numerous publications discuss the functional 
relationships between induced mutations and/or adducts and 3-NBA 
dose (39,44,70,71).
Least-squares linear regression was employed to examine empiri-
cal relationships between MF and total RAL in tissues/cells that 
yielded significant dose-related increases. The results for colonic 
epithelium are illustrated in Figure 4. The difference in the slopes 
of the relationship between mean MF and mean total RAL indicate 
a higher total yield of lacZ mutants for 28-day sampling in com-
parison with 3-day sampling. Although these results are interest-
ing, analysis of the relationship between average MF and average 
total RAL does not maximise the number of degrees of freedom for 
linear regression analysis and slope determination. However, varia-
tion in the number of total RAL and MF observations for each dose 
complicates use of the entire dataset for each tissue-sampling time 
combination. Accordingly, a repeated random sub-sampling routine 
(i.e., bootstrapping) was employed to maximise the use of the data 
and provide unbiased estimates of the slope of the MF-RAL rela-
tionships. For a given tissue and sampling time, the bootstrapping 
routine randomly selected appropriately sized groups of replicates 
for MF and total RAL at each dose, and then employed least-squares 
regression to determine the slope. One thousand iterations of this 
process provided a distribution of slope values. The results obtained, 
which are displayed in Figure 5, show that the average bootstrapped 
slope of the MF-RAL relationship, a metric henceforth termed the 
mutagenic efficiency of total adducts, is lowest in liver (28  days), 
greater in colon (3 and 28 days) and bone marrow (18 h and 3 days), 
and finally highest in FE1 cells exposed in vitro. Importantly, since 
the Muta™Mouse assay only permits the detection of total MF, it 
was not possible to examine the mutagenic efficiency of individual 
adducts (9,20,21). Table  2 summarises the results of the boot-
strapped linear regression results for each tissue and sampling time 
combination that yielded significant increases in both MF and total 
RAL. Although all slope values are significantly greater than zero, 
indicating that total MF increases with increasing total RAL, the 
bootstrapped F ratios indicate that the ANOVA results for colon 
(3-day sampling) and liver are not significant at p<0.05. This incon-
gruence suggests that, for some tissues, additional statistical power 
(e.g., additional doses and/or replicates) is required to conclusively 
demonstrate relationships between total MF and total RAL (i.e., 
effectively reduce the likelihood of a Type II error).
In their review that discusses the use of DNA adduct data in can-
cer risk assessment, Jarabek et al. (9) note that the likelihood that a 
Figure 4. The empirical relationship between mutant frequency (MF) and total RAL (relative adduct labelling) in colonic epithelium. All RAL observations were 
made 18 h after treatment. MF observations were made 3 and 28 days after treatment. No significant increase in MF was observed 18 h after treatment. Error 
bars show one standard error of the mean. Slope values were calculated using ordinary least-squares linear regression.
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particular DNA adduct or adduct load will result in mutation, a con-
cept referred to as mutagenic efficiency, is dependent on a number 
of factors including the frequency of cellular replication. The mitotic 
index (MI) of cells in several tissues has been determined in numer-
ous rodent studies, and a review of published values (N = 4–15 per 
tissue) provided averages of 0.36 ± 0.07%, 2.1 ± 0.2%, 0.14 ± 0.04, 
4.8 ± 1.5, and 5.0 ± 0.8% for liver, colonic epithelium, lung, small 
intestine and bone marrow, respectively (54–67). Although tissue-
specific MI values for the Muta™Mouse are not available, the MI 
for the Muta™Mouse FE1 cell line is 14.1 ± 2.4% (49). Although 
the above in vivo values do not account for variations among cell 
populations in a given tissue (e.g., crypt position, different haema-
topoietic cells, etc.), they correlate with the maximum slope of the 
observed empirical relationships between MF and total RAL for 
liver, colon, bone marrow and FE1 cells. The results, which are illus-
trated in Figure 6, show a significant positive effect of mitotic index 
on the maximum observed mutagenic efficiency of total adducts. 
Although a significant increase in lacZ MF was not observed for 
lung, and concomitantly, the slope of MF-total RAL relationship for 
lung is zero, the low MI of lung cells (72) suggests that the slope 
of the MF-total RAL relationship would be lower than liver and 
extremely shallow. The lack of increase in MF in small intestine 
also results in a zero slope for the MF-total RAL relationship. The 
bootstrapped linear regression analysis based on all observations 
(Figure 6) revealed a significant positive relationship (i.e., r2 = 0.67, F 
Ratio = 10.1, P < 0.02). As expected, the intercept is not statistically 
different from zero (i.e., 0.05  ±  0.12). Examination of regression 
diagnostics (e.g., leverage and Studentised residuals) was employed 
to assess model misspecification and the influence of individual 
observations. Residual value analyses did not support any notion 
of model misspecification, and leverage (i.e., hi) analyses revealed 
that the FE1 observation is influential. This is not at all surprising 
given the distance of its MI from the mean MI across all tissues/
cells. Importantly, the Studentised residual for the FE1 observation 
is exceptionally small, revealing that there is no objective justifica-
tion for its removal from the dataset. On the contrary, the value 
is in line with observations for lung, liver and colon (i.e., increase 
in the mutagenic efficiency of total adducts is proportional to the 
Figure 5. Distribution of bootstrapped slope values for the relationships between mutant frequency (MF) and total RAL (relative adduct labelling) for each 
tissue and sampling time combination that yielded a significant response. Slope values were calculated via least-squares regression on data selected using 
a sub-sampling routine that randomly chose MF and RAL values at each dose. Each distribution represents 1000 iterations of the sampling routine and slope 
calculation. The box limits represent the interquartile range (i.e., 25th and 75th percentiles), and the whiskers show the 5th and 95th percentiles. Symbols located 
beyond the whiskers are outliers. The solid line is the median value and the dotted line the arithmetic mean. All mean slope values (Table 2) are significantly 
greater than zero. P values show the ANOVA probability for rejection of the null hypothesis that total MF is not empirically related to total RAL. Letters above 
plots show the results of post hoc contrasts. When boxes are accompanied by the same letter, the mean slope values (i.e., mutagenic efficiency of total adducts) 
are not significantly different at P < 0.05.
Table 2. Summary of bootstrapped linear regression results for the relationships between lacZ MF and total RAL
Tissue/Sampling Time Mean Slope ± SEM Mean r2 Mean F Ratio df ANOVA Mean P value
Liver: 28-day sampling 0.038 ± 0.014* 0.19 0.64 18 0.34
Colon: 3-day sampling 0.089 ± 0.018*** 0.29 1.59 18 0.21
Colon: 28-day sampling 0.24 ± 0.023*** 0.66 7.74 18 0.011
Bone marrow: 18-h sampling 0.89 ± 0.0059*** 0.76 13.25 10 0.0043
Bone marrow: 3-day sampling 0.99 ± 0.17*** 0.51 4.09 15 0.050
FE1 cells: 3-day sampling 1.62 ± 0.21*** 0.83 22.34 9 0.00087
The results shown, which represent the average of 1000 regression iterations, are provided for each tissue and sampling time. df indicates the degrees of freedom 
associated with each regression.
SEM, standard error of the mean.
*P < 0.05, **P < 0.01, ***P < 0.001.
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increase in MI). Analysis of Studentised residuals and Studentised 
deleted residuals revealed that the small intestine observation is a 
marginally significant negative outlier (i.e., Studentised deleted resid-
ual = -2.46, P = 0.057). This justifies its removal for reanalysis of the 
data. Exclusion of small intestine from the regression analysis yields 
slightly different results (i.e., r2 = 0.85, F Ratio = 59.4, P < 0.002); 
however, the slopes of the two models are not significantly different 
(i.e., 0.098 ± 0.034 versus 0.110 ± 0.016).
Discussion
Our earlier work showed that single oral doses of 25 and 50 mg/kg 
3-NBA induced significant increases in lacZ MF in Muta™Mouse 
colonic epithelium, and in both bone marrow and colonic epithe-
lium, respectively (48). However, single acute exposures did not elicit 
significant increases in lacZ MF in bladder or liver. The same study 
showed that 28-day repeat-dose oral exposures to 2 and 5 mg/kg 
induced significant increases in MF in bone marrow, and both bone 
marrow and liver, respectively. Also, repeated dose administration 
did not yield significant increases in MF in lung or intestinal epithe-
lium. That study (48) employed a recommended sampling time of 
3 days for bone marrow, 28 days for liver, lung, colonic and intesti-
nal epithelium (73,74). Similarly, in another study, we also showed 
that a 28-day repeated dose oral exposure of 2 or 5 mg/kg, followed 
by a 28-day sampling time, induced a significant increase in MF in 
bone marrow and liver (37), but showed no significant increase in 
MF in lung and intestinal epithelium at any dose. Both studies (i.e., 
(37,48)) also showed a significant increase in MF in Muta™Mouse 
FE1 cells exposed to 3-NBA in vitro (0.1, 1, 3 and 10 µg/ml).
The 28-day repeated dose study showed significant levels of 
DNA adducts in liver, lung and bone marrow in Muta™Mouse (37). 
Moreover, significant levels of DNA adducts were detected in FE1 
cells exposed to 3-NBA (37). These results, in conjunction with ear-
lier rodent studies in Muta™Mouse, Wistar and SD rat, confirm sig-
nificant increases in 3-NBA adducts in numerous tissues such as liver, 
lung, bone marrow, colon, intestine, bladder, stomach and kidney, 
but significant increases in MF only for selected tissues such as colon, 
liver and bone marrow (41,45,75).
Lambert et al. (28,29) noted that in vivo mutation detection mod-
els such as the Muta™Mouse can be used to examine virtually any tis-
sue, with the response to a given dose in a given tissue being influenced 
by route of administration, toxicokinetics, tissue-specific DNA repair, 
tissue specific mitotic index and the nature of the genetic target. The 
Muta™Mouse system is well-suited to the analysis carried out in this 
study, since the multi-copy transgene (i.e., 29 ± 4 copies) (76) is neu-
tral (i.e. transcriptionally inactive), and therefore, not subject to tran-
scription coupled repair. Accordingly, by default, the dominant mode 
of DNA repair operating on 3-NBA adducts will be global genomic 
repair, a system that should be fully active during the course of the 
experiment. Interestingly, recent work by Kucab et al. (44) indicates 
that 3-NBA adducts may evade removal by global genomic nucleotide 
excision repair, and the authors suggest that resultant adduct persis-
tence may be playing a significant role in 3-NBA mutagenicity.
The results obtained herein showed that a significant increase in 
total 3-NBA-DNA adducts can be detected in bone marrow, liver, 
intestinal and colonic epithelium and lung 18 h after oral administra-
tion of a single dose. Moreover, the most frequent adduct detected in 
all tissues/cells examined is dG-N2-3-ABA (Figure 3, Supplementary 
Figure 1, available at Mutagenesis Online, spot 3), a promutagenic 
adduct (17,43,46) that is approximately 4- to 9-fold more persis-
tent than the other 3-NBA-induced adducts ((17,43); Supplementary 
Table 1, available at Mutagenesis Online). However, mutational anal-
yses revealed significant increases in lacZ MF only for bone marrow, 
liver and colonic epithelium; significant increases in MF for lung and 
intestinal epithelium were not observed, despite significant elevation 
in adducts. The lack of lacZ mutants in the latter tissues included 
results from multiple (intestine) and/or extended (lung) sampling 
times ranging from 18 h to 28 days. Additionally, our earlier work 
showed that 3-ABA, the reduced metabolite of 3-NBA, also failed 
to induce a significant increase in lacZ mutations in Muta™Mouse 
lung (37). Interestingly, other researchers have detected significant 
increases in lacZ MF in lung and intestine following exposures to 
other homo- or heterocyclic aromatic compounds. For example, 
numerous studies have shown significant increases in lung MF, in 
some cases as high as 28-fold above concurrent control, following 
oral exposures to PAHs such as benzo[a]pyrene and dibenz[a,h]
anthracene (Supplementary Table 2, available at Mutagenesis Online). 
Similarly, several studies have shown significant increases in small 
intestine MF, in some cases as high as 170-fold above concurrent 
control, following exposures to a range of homo- or heterocyclic aro-
matic compounds (Supplementary Table 2, available at Mutagenesis 
Online). Interestingly, the lung data summarised in Supplementary 
Figure 6. The effect of mitotic index on the slope of the relationships between mutant frequency (MF) and RAL (relative adduct labelling) for different tissues/
cells. No lacZ mutants were detected in lung and small intestine, and the MF-RAL slopes for these tissues are zero. The inset shows the results of bootstrapped 
linear regression analysis. Exclusion of the small intestine observation yields slightly different results (see text). Vertical and horizontal error bars show one 
standard error of the mean. Where error bars cannot be seen, the bars were smaller than the plotting symbol. Mitotic index values, which were collected from 
the published literature, are expressed as the percentage of examined cells undergoing DNA replication and/or mitosis. Four to fifteen values were collected for 
each tissue shown; values represent several strains of rodents and multiple adult ages. The majority of studies employed microscopic analyses of Geimsa or 
H&E (hematoxylin and eosin) stained tissues. A small number of studies used autoradiography to quantify the proportion of cells in S-phase. 
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Table 2, available at Mutagenesis Online, includes data from a study 
by Kohara et al. (77) that documented a significant 1.6-fold increase 
in MF following 28-day repeat dose intragastric administration of 
a dinitropyrene mixture. Thus, the lack of 3-NBA-induced lacZ 
mutants in lung and small intestine observed in the current study can 
reasonably be regarded as atypical for the Muta™Mouse.
The results shown herein confirm that all examined tissues 
were exposed to the genotoxic metabolite(s) of 3-NBA (Figure  2). 
Moreover, despite some aforementioned exceptions (e.g., lung spots 
2 and 4), there is minimal cross-tissue variation in the 3-NBA adduct 
profiles, and the predominant adduct in all samples examined is dG-
N2-3-ABA (37). Nevertheless, although some tissues showed high 
levels of total adducts (e.g., liver, Figure 2), and a high proportion of 
the total comprised of an adduct that is known to be both persistent 
and promutagenic (Supplementary Table 1, available at Mutagenesis 
Online, (42,43,46)), the yield of lacZ mutants for some tissues was 
modest (e.g., liver, Figure 1) and clearly dependent on factors other 
than DNA damage frequency. Consequently, the mean slopes of 
the relationships between lacZ MF and total RAL varies consider-
ably across tissues (Figure 5). For example, the results illustrated in 
Figure 5 and Table 2 indicate a 2.3-fold difference in slope between 
28-day liver and 3-day colon, and a ~6-fold difference between 28-day 
liver and 28-day colon. This variation in the slope, also referred to 
as the mutagenic efficiency of total adducts, is likely dependent on 
tissue-specific factors, such as differential repair and/or differences in 
replicative capacity, which in turn influence mutation manifestation 
time (Figure 4). This notion is supported by the Lambert et al. sum-
mary of transgenic rodent mutagenicity data (28,29), which showed 
that extended sampling times for slowly dividing tissues (e.g., liver) 
generally yield higher induced mutant frequencies. Since maximum 
MF is a function of sampling time, it seems reasonable to hypoth-
esise that tissue-specific cell turnover has a major influence on the 
yield of lacZ mutants in the samples analysed herein, and hence the 
mutagenic efficiency of total 3-NBA adducts. Indeed, the empirical 
relationship between the maximum observed mutagenic efficiency 
of total adducts and MI supports this hypothesis (Figure 6), which 
is consistent with earlier reports in the literature. In their analyses 
of 1,2,3-trichloropropane, La et  al. (78) noted the importance of 
cell proliferation in understanding of the biological significance of 
DNA adduct frequency measurements. Ochiai et al. (79) showed that 
2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-DNA adduct levels 
do not correlate with lacI MF in Big Blue® mouse tissues, and the 
authors asserted that observed MF is likely determined by both tis-
sue-specific adduct levels and cellular proliferation rates.
The contention that tissue-specific cell turnover is having a strong 
influence on the yield of 3-NBA-induced lacZ mutants, and hence 
the mutagenic efficiency of total 3-NBA adducts, is consistent with 
the similarity in adduct profiles across the tissues examined. Little 
variations in adduct profiles across the tissues examined (Figure 3), 
and the predominance of the most persistence and promutagenic 
adduct (i.e., dG-N2-3-ABA, Spot 3) (Supplementary Table 1, avail-
able at Mutagenesis Online, (42,43,46)), also supports the notion 
that other factors, such tissue-specific cell turnover, are influencing 
the yield of 3-NBA-induced lacZ mutants, and hence the mutagenic 
efficiency of total 3-NBA adducts. Nevertheless, it is also impor-
tant to note that clonal expansion of proliferating cells containing 
a lacZ mutation may augment MF, thereby increasing the apparent 
efficiency of total adducts. However, proportionally scaled increases 
in clonal expansion would be expected to equivalently augment the 
mutagenic efficiency of total adducts in all tissues. Indeed, recent 
next-generation sequencing of induced lacZ mutants failed to show 
cross-tissue variations in the proportion of the total mutants at a 
given dose resulting from clonal expansion (unpublished data).
The results presenteed in Figure 6 and Table 2 raise a range of 
interesting issues related to the in vivo toxicokinetics of 3-NBA, as 
well as tissue-specific difference in 3-NBA metabolism, processing 
of 3-NBA-induced damage, and tissue-specific replicative capacity. 
For example, the results show stark contrast between the effects of 
3-NBA on lung tissue and FE1 cells, despite the fact that FE1 cells 
were derived from Muta™Mouse lung. More specifically, the muta-
genic efficiency of total adducts is high for FE1 cells and zero for 
lung. This discrepancy is a direct consequence of the absence of lacZ 
mutants in lung tissue, and a significant increase in lacZ MF in FE1 
cells (Figure 2 herein and Figure 2a and 4a in Arlt et al. (37)), despite 
the fact that total RAL was significantly elevated in both, and both 
are clearly exposed to an adduct that has been shown to be both 
persistent and promutagenic (i.e., dG-N2-3-ABA, Supplementary 
Table 1, available at Mutagenesis Online, (42,43,46)). Since FE1 cells 
retain numerous characteristics of alveolar epithelium (80), there is 
no reason to assert that the majority of the factors controlling the 
frequencies of mutations (e.g., capacity for repair, translesion syn-
thesis, etc.) differ between Muta™Mouse lung tissue and FE1 cells. 
Thus, it seems reasonable to assert that the difference in adduct load 
is driven by cellular dose, and the difference in the mutagenic effi-
ciency of total adducts is driven by the 100-fold difference in mitotic 
index (i.e., 14.1% versus 0.14%). With respect to the former, it is 
reasonable to emphasise that cells exposed in vitro will come into 
contact with a far greater amount of parent compound than an in 
vivo tissue that is remote from the site of first contact (i.e., GI tract). It 
is also necessary to acknowledge that the difference in adduct load at 
a given time point may also be driven by differences in exposures to 
reactive metabolites, and/or differences in damage processing. With 
respect to the former, Bendt-Weiss et al. (80) investigated changes in 
cyp1a1, cy1a2 and cyp1b1 gene expression in FE1 cells and lung tis-
sue following exposures to benzo[a]pyrene (BaP). The results showed 
significant increases in cyp1a1, cyp1a2 and cyp1b1 expression in 
FE1 exposed in vitro, but no significant increases in either cyp1a1 or 
cyp1a2 in Muta™Mouse lung exposed in vivo. This difference, which 
may result from reduced in vivo exposure of metabolically-competent 
lung cells to a parent compound such as BaP, may also contribute to 
the reduced lung effect observed herein. Alternatively, Muta™Mouse 
lung may have a limited relative capacity to convert 3-NBA to the 
aforementioned metabolite N-hydroxy-3-aminobenzanthrone. This 
seems unlikely since the in vivo and in vitro analyses showed sig-
nificant increases in 3-NBA adducts in Muta™Mouse lung tissue and 
cells derived from Muta™Mouse lung tissue.
The bootstrapped relationship presented in Figure 6 indicates that 
the mean of published lung MI values (i.e., 0.14 ± 0.044%) would 
correspond to a predicted mutagenic efficiency of total adducts of 
0.068 ± 0.16, a value that is not significantly different from zero. Thus, 
as noted above, it seems highly likely that the inability of 3-NBA oral 
exposure to induce a significant increase in MF in the lung is primarily 
due to low MI. Shami and Evans (72) have indicated that although 
the proliferative indices of pulmonary cells varies according to cell 
type and animal age, the proportion of cells in adult rodents in M or S 
phase is generally very low. More specifically, MI values for adult rat 
bronchiolar/tracheal basal and nonciliated cells ranges from 0.05 to 
0.25%. Similarly, the proportion of adult rat Clara and alveolar Type 
II cells in S phase ranges from 0.1 to 1.1% and 0.1 to 0.5%, respec-
tively. Similar Clara cell values have been recorded for adult mouse and 
hamster (i.e., 0.16 and 0.3%, respectively). Nevertheless, some studies 
have recorded relatively high proportions of Type II cells in S phase 
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(i.e., 1.1–2.9% in adult hamster). The earlier Arlt et al. (45) study that 
investigated 3-NBA-induced adducts and lacZ MF in Muta™Mouse 
following ip injection also did not detect significant increases in MF in 
the lung, in addition to kidney, spleen and testis. The authors of that 
study also highlight studies noting how the slow cell turnover in lung 
can reduce the likelihood of observing significant elevations in lung 
MF (73,74). Although the contrast between in vivo lung tissue results 
and FE1 cell results, presented both here and elsewhere, suggests that 
extrapolations from in vitro to in vivo should be done with caution, 
there is no evidence to support the notion that these differences are 
driven by important metabolic and/or genetic differences.
Although the adduct frequency in lung is relatively low, it is signifi-
cantly above zero and comparable to that observed in the bone marrow, 
thus indicating that the lung is clearly exposed to reactive metabolites. 
Nevertheless, the low levels of 3-NBA-DNA adducts in lung, relative to 
liver, colon and bone marrow, suggest low exposure of Muta™Mouse 
lung to reactive 3-NBA metabolites. This result is supported by the Arlt 
et al. (45) study and similar results were obtained in a recent murine 
study of benzo[a]pyrene; DNA adduct levels in lung ~10-fold lower 
than liver 24 h after a single i.p. injection of 2 mg/kg body weight (70). 
However, this contrasts with the results of Long et al. (81) who noted 
statistically elevated levels of adducts in Muta™Mouse lung following 
28-day repeat dose oral exposures to nine polycyclic aromatic hydro-
carbons (PAHs), despite a lack of total adduct increases in bone mar-
row, liver, intestine, and/or glandular stomach for selected compounds 
(81). More specifically, for benzo[a]pyrene only, total adduct levels in 
lung were 1.8- to 3.3-fold greater than liver (81,82). The Arlt et al. find-
ings also contrast rat studies that showed high levels of 3-NBA-induced 
adducts in lung following i.p. injection (45,75). The reason for these 
discrepancies across compounds, rodent species, and/or rodent strains, 
is not known; however, it seems likely that selected murine tissues lack 
the enzymatic capacity to carry out the initial nitroreduction that is 
essential for the formation of 3-NBA N-hydroxyarylamine intermedi-
ates, and ultimately the DNA-reactive metabolites harbouring nitre-
nium or carbenium ions (36,37). Nevertheless, this contention is not 
supported by Chen et al. (48), who confirmed that levels of 3-NBA 
reductase in Muta™Mouse lung are actually quite high relative to liver, 
colon, bone marrow and bladder.
It is also reasonable to hypothesise that lack of repair, and/or error-
prone translesion synthesis (TLS), of 3-NBA-induced DNA damage 
could alter mutation fixation in tissues such as lung. Kucab et  al. 
(44), recently suggested that the mutagenic potency of 3-NBA may 
be enhanced by an ability of 3-NBA adducts to avoid global genomic 
nucleotide excision repair. In addition, several studies have noted 
that DNA polymerase κ (kappa) can bypass BaP-induced dG lesions 
(i.e., BPDE-N2-dG) in a predominantly error-free manner (83–86). 
However, in contrast, Pande et al. (17) showed that Pol κ and Pol η 
are major contributors to mutagenic TLS of dG-C8-N-3-ABA adducts 
in human embryonic kidney 293T (HEK293T) cells. Interestingly, 
Ogi et al. (83) showed that both mouse and human Polk genes have 
upstream AhR (Ah-receptor) binding sites; possibly making gene 
expression and lesion bypass AhR-inducible. These authors further 
note that Pol κ can reduce the mutagenicity of some bulky PAH 
adducts in some tissues; with levels of POLk protein in lung enhanced 
following i.p. administration of 3-methlycholanthrene. This finding is 
supported by the work of Stancel et al. (87) who showed increased 
lacI MF in lung, liver and kidney of Polk knock-out BigBlue® mice. 
Whether TLS in lung serves to augment or diminish the conversion of 
3-NBA adducts to fixed mutations in vivo remains to be determined.
Total RAL levels in intestinal epithelium are also low, but they 
are significantly greater than zero, and this tissue was also clearly 
exposed. Given that published MI values for small intestine are often 
as high as bone marrow, the absence of a relationship between MF 
and total adducts was unexpected. Although published mitotic index 
values for intestinal epithelium vary according to intestinal seg-
ment and position within villi and crypts, values are generally in the 
3–15% range. The geometric mean MI from four reviewed studies is 
4.8 ± 1.5% (88–91), and based on the bootstrapped relationship pre-
sented in Figure 6, this value would correspond to a predicted muta-
genic efficiency of total adducts of 0.52 ± 0.15, a value that would fall 
between colon and bone marrow (Figures 5 and 6). Using the RAL 
results presented in Figure 2, the predicted small intestine MF associ-
ated with 25, 50 and 75 mg/kg would be ~1.5 × 10–5, a value that 
would not be significantly greater than the concurrent controls (i.e., 
9.4 ± 1.6 × 10–5 for 3 days and 18.2 ± 5.5 × 10–5 for 28 days). Taking 
into account the aforementioned factors that affect adduct formation 
and the mutagenic efficiency of total adducts, it seems reasonable to 
suppose that the absence of response in both lung and intestine are 
likely driven by a combination of low mitotic index (lung only), low 
levels of exposure to reactive metabolites, and tissue-specific differ-
ences in adduct processing. It should be noted that since the process-
ing of small intestine tissue involved removal of luminal contents and 
tissue rinsing (see Methods and Materials), it seems unlikely that the 
results obtained (i.e., DNA adducts, but no mutations) are related to 
bacterial contamination of murine DNA samples.
Despite the aforementioned expectations, the difference between 
small intestine and other tissues observed herein (e.g., liver, colon 
and bone marrow) are consistent with earlier works that examined 
digestive tract effects of 3-NBA and other nitroarenes. The afore-
mentioned Kohara et al. (77) study noted that intragastric adminis-
tration of a dinitropyrene mixture readily induced large increases in 
lacZ MF in Muta™Mouse colon (Supplementary Table 2, available 
at Mutagenesis Online). Although small intestine was not examined 
in that study, the colon MF levels were more than 2-fold greater 
than those observed for stomach. Arlt et  al. (45) suggest that the 
greater colonic effect of nitroarenes such as 3-NBA may be related to 
enhanced nitroreduction by colonic bacteria. They further note that 
the strong mutagenic effect of 3-NBA in Muta™Mouse colon fol-
lowing i.p. administration is consistent with reports of high adduct 
levels in the colon, relative to small intestine or stomach, in rats and 
mice exposed either orally or by i.p. injection (41,45,70,75).
The inability to observe significant increases in lacZ MF in the 
small intestine may also be related to a high frequency of induced 
apoptosis. It is well known that small intestine is exceptionally sen-
sitive to radiation and chemical mutagens, displaying high rates 
of induced apoptosis in rapidly proliferating crypt cells (92–94); 
high frequency chemically induced apoptosis in intestinal epithelia 
may restrict the ability to recover induced lacZ mutants following 
oral exposures. Nevertheless, Lynch et al. (95) and Itoh et al. (96) 
did show significant increases in lacZ MF in Muta™Mouse small 
intestine following 4 or 5 daily oral exposures to PhIP, respectively 
(Supplementary Table 1, available at Mutagenesis Online). In addi-
tion, the aforementioned Long et  al study of nine PAHs showed 
robust DNA damage and mutagenicity responses in Muta™Mouse 
small intestine following 28-day oral exposures (81). However, it 
should be emphasised that each of the highlighted studies examined 
intestinal tissues after several daily administrations; whereas, the 
current study examined tissues after a single acute dose. Interestingly, 
a study of urethane by Singer (97) detected significant increases in 
lacZ MF in small intestine only following consecutive daily treat-
ments for 28 or 56  days; treatments for 7  days did not induce a 
significant MF increase.
10 P. A. White et al.
Conclusions and implications
The quantitative relationship between total DNA damage frequency 
and induced MF has rarely been explored. In an ideal situation, suf-
ficient information on the quantitative relationship between adduct 
frequency (i.e., a marker of exposure and internal dose) and MF (i.e., 
an adverse effect on the exposed tissue), for noteworthy environmen-
tal mutagens, would permit use of the former to determine the risk 
of the latter; moreover, the risk of adverse health effects that have 
been mechanistically associated with the latter (i.e., cancer, heritable 
genetic disorders). As noted, MF will be a function of the production 
of DNA-reactive metabolites, DNA damage frequency, the probability 
of repair and the probability that the damaged site will be misread 
during replication. The latter factor implies that the frequency of 
chemically-induced mutations will be dependent on the proliferation 
index of damaged cells in the exposed tissue. The results presented 
here confirm that there is a significant positive effect of tissue-specific 
mitotic index on the maximum observed tissue-specific mutagenic effi-
ciency of total adducts. However, some tissues, such as small intestine, 
do not follow the observed empirical relationship. In this tissue, the 
MF observed at selected sampling time(s) following an acute 3-NBA 
exposure does not appear to be empirically related to MI. In contrast, 
the mutagenic efficiency of total adducts for other tissues (i.e., bone 
marrow) is higher than that predicted by the empirical relationship 
shown in Figure 6. In the latter case, clonal expansion of cells con-
taining a mutant lacZ may be increasing the measured MF and the 
apparent mutagenic efficiency of total adducts; nevertheless, clonal 
expansion of mutants is likely having a proportionally scaled effect on 
other tissues. It should be noted that the mutagenic efficiency of total 
adducts, particularly for slowly proliferating tissues, may also be influ-
enced by cellular replication induced by the cytotoxicity of the tested 
compound. For example, Tombolan et al. (98) noted that the marked 
increases in hepatic MF of Muta™Mouse exposed to elevated lev-
els 5,9-dimethydibenzo[c,g]carbazole (DMDBC) corresponded with 
increased levels of cytotoxicity-induced cellular proliferation.
The restricted nature of the data presented in Figure 6 diminishes 
the ability to make general statements regarding the interpretation of 
DNA adduct data in a risk assessment context. Although tissue-spe-
cific frequencies of DNA adducts do provide an indication of target 
tissue dose, the risk of adverse effect in tissues with relatively high pro-
liferative capacity can be diminished in some tissues relative to other 
similar tissues (e.g., small intestine versus colon). The reasons under-
lying these differences are unclear and may be compound-specific, 
with variations in tissue-specific handling of DNA damage almost 
certainly altering the tissue-specific risk of mutation. Nevertheless, it 
is important to emphasise that an absence of tissue-specific, promuta-
genic DNA adducts will be associated with an absence of risk.
Although the results presented support the assertion that the 
risk of tissue-specific mutation formation is dependent, in part, 
on damage frequency and proliferative capacity, the likely roles of 
compound-specific distribution and metabolism, tissue-specific dam-
age processing, exposure regime and post-exposure sampling time, 
intratissue variations in replicative capacity, and the nature and 
magnitude of tissue-specific responses to toxic insults, indicate that 
further work is required prior to any general statement regarding the 
ability to interpret adduct frequency in a disease risk context (e.g., 
additional tissues, additional cells in vitro, wider range of sampling 
times). In addition, the empirical analyses of the relationship between 
the maximum observed mutagenic efficiency of total adducts and 
MI (i.e., Figure 6; Table 2) indicate that more doses are required to 
obtain robust results for slowly proliferating tissues (e.g., liver). It 
seems likely that the nature and magnitude of empirical relationships 
between the mutagenic efficiency of total adducts and proliferative 
index will depend on compound type, making it possible to make 
general statements for distinct classes of environmental mutagens.
This work provides a proof of principle regarding the use of the 
Muta™Mouse system to critically examine the health risks associ-
ated with tissue-specific total adduct loads, which will be employed 
in future studies to provide a stronger context for the interpretation 
of DNA adduct frequency values for selected classes of environmen-
tal mutagens. Indeed, we are already scrutinising the relationships 
between induced MF and total adduct frequency for a series of PAHs.
Supplementary data
Supplementary  data are available at Mutagenesis Online.
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